{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:43:52Z","timestamp":1793738632498,"version":"4.6.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.berh.2021.101716","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T06:20:42Z","timestamp":1634019642000},"page":"101716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The challenge of gout flare measurement"],"prefix":"10.1016","volume":"35","author":[{"given":"Sarah","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Gaffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.berh.2021.101716_bib1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/acr.23607","article-title":"Gout, Hyperuricemia, and Crystal-Associated Disease Network consensus statement regarding labels and definitions for disease elements in gout","volume":"71","author":"Bursill","year":"2019","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.berh.2021.101716_bib2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/art.1780150209","article-title":"The influence of temperature on the solubility of monosodium urate","volume":"15","author":"Loeb","year":"1972","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2021.101716_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/1054773818769219","article-title":"A\u00a0qualitative study exploring perceptions of patients with gout","volume":"29","author":"Seow","year":"2020","journal-title":"Clin Nurs Res"},{"issue":"1","key":"10.1016\/j.berh.2021.101716_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/RHU.0b013e318204a8f9","article-title":"The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach","volume":"17","author":"Lindsay","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2021.101716_bib5","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s10067-013-2400-6","article-title":"Experiences of gout-related disability from the patients' perspective: a mixed methods study","volume":"33","author":"ten Klooster","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2021.101716_bib6","doi-asserted-by":"crossref","DOI":"10.1186\/ar4589","article-title":"The impact of gout on patient's lives: a study of African-American and Caucasian men and women with gout","volume":"16","author":"Singh","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2021.101716_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40271-016-0184-x","article-title":"What outcomes are important for gout patients? In-depth qualitative research into the gout patient experience to determine optimal endpoints for evaluating therapeutic interventions","volume":"10","author":"Tatlock","year":"2017","journal-title":"Patient"},{"issue":"3","key":"10.1016\/j.berh.2021.101716_bib8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3899\/jrheum.131258","article-title":"Research priorities in gout: the patient perspective","volume":"41","author":"Singh","year":"2014","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2021.101716_bib9","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3899\/jrheum.071229","article-title":"Quality of life and disability in patients with treatment-failure gout","volume":"36","author":"Becker","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2021.101716_bib10","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.berh.2021.101716_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13075-020-02254-4","article-title":"Development of a multivariable improvement measure for gout","volume":"22","author":"Schlesinger","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.berh.2021.101716_bib12","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3899\/jrheum.110274","article-title":"Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials","volume":"38","author":"Taylor","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2021.101716_bib13","series-title":"Heraclitus. Hippocrates","first-page":"31","author":"Hippocrates","year":"1923"},{"key":"10.1016\/j.berh.2021.101716_bib14","series-title":"Oeuvres compl\u00e8tes d'Hippocrate","author":"Hippocrates","year":"1839"},{"key":"10.1016\/j.berh.2021.101716_bib15","series-title":"Tractatus de Podagra et Hydrope","author":"Sydenham","year":"1685"},{"issue":"6","key":"10.1016\/j.berh.2021.101716_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jama.1941.02820060001001","article-title":"Diagnosis and treatment of gout and gouty arthritis","volume":"116","author":"Hench","year":"1941","journal-title":"J\u00a0Am Med Assoc"},{"issue":"4","key":"10.1016\/j.berh.2021.101716_bib17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/art.1780160402","article-title":"The past four decades of progress in the knowledge of gout, with an assessment of the present status","volume":"16","author":"Gutman","year":"1973","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2021.101716_bib18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/ard.29.5.461","article-title":"Clinical survey of 354 patients with gout","volume":"29","author":"Grahame","year":"1970","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2021.101716_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2125.1987.tb03132.x","article-title":"Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs","volume":"24","author":"Bellamy","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.berh.2021.101716_bib20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41927-019-0075-6","article-title":"The challenges of gout flare reporting: mapping flares during a randomized controlled trial","volume":"3","author":"Teoh","year":"2019","journal-title":"BMC Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2021.101716_bib21","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/art.39254","article-title":"Gout classification criteria: an American College of Rheumatology\/European League against rheumatism collaborative initiative","volume":"67","author":"Neogi","year":"2015","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.berh.2021.101716_bib22","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3899\/jrheum.090370","article-title":"Outcome domains for studies of acute and chronic gout","volume":"36","author":"Schumacher","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2021.101716_bib23","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.3899\/jrheum.090371","article-title":"Progress in measurement instruments for acute and chronic gout studies","volume":"36","author":"Grainger","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2021.101716_bib24","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3899\/jrheum.131245","article-title":"Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout","volume":"41","author":"Taylor","year":"2014","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2021.101716_bib25","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.3899\/jrheum.110271","article-title":"Patient-reported outcomes in chronic gout: a report from OMERACT 10","volume":"38","author":"Singh","year":"2011","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2021.101716_bib26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/BOR.0b013e3282f36cf1","article-title":"Establishing outcome domains for evaluating treatment of acute and chronic gout","volume":"20","author":"Grainger","year":"2008","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2021.101716_bib27","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/ard.2007.079970","article-title":"A\u00a0modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout","volume":"67","author":"Taylor","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2021.101716_bib28","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3899\/jrheum.131246","article-title":"OMERACT endorsement of measures of outcome for studies of acute gout","volume":"41","author":"Singh","year":"2014","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2021.101716_bib29","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/rheumatology\/keu424","article-title":"Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review","volume":"54","author":"Ara\u00fajo","year":"2015","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.berh.2021.101716_bib30","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/rheumatology\/kez064","article-title":"Development and validation of a patient-reported gout attack intensity score for use in gout clinical studies","volume":"58","author":"Janssen","year":"2019","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.berh.2021.101716_bib31","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/rheumatology\/kez198","article-title":"Outcome measurement in acute gout: about constructs, perspectives, scales and timing","volume":"58","author":"Vranken","year":"2019","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2021.101716_bib32","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/art.33483","article-title":"Developing a provisional definition of flare in patients with established gout","volume":"64","author":"Gaffo","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2021.101716_bib33","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/art.24166","article-title":"Toward a valid definition of gout flare: results of consensus exercises using Delphi methodology and cognitive mapping","volume":"61","author":"Taylor","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2021.101716_bib34","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/art.40381","article-title":"Brief report: validation of a definition of flare in patients with established gout","volume":"70","author":"Gaffo","year":"2018","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2021.101716_bib35","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s40674-015-0014-7","article-title":"Outcome measures for gout clinical trials: a summary of progress","volume":"1","author":"de Lautour","year":"2015","journal-title":"Curr Treat Options Rheumatol"},{"key":"10.1016\/j.berh.2021.101716_bib36","first-page":"S11","article-title":"Measurement of outcome in gout","volume":"8","author":"Taylor","year":"2013","journal-title":"Ind J Rheumoatol"},{"issue":"2","key":"10.1016\/j.berh.2021.101716_bib37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.semarthrit.2019.11.002","article-title":"How flare prevention outcomes are reported in gout studies: a systematic review and content analysis of randomized controlled trials","volume":"50","author":"Stewart","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2021.101716_bib38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3899\/jrheum.170911","article-title":"Variability in the reporting of serum urate and flares in gout clinical trials: need for minimum reporting requirements","volume":"45","author":"Stamp","year":"2018","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2021.101716_bib39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3899\/jrheum.191242","article-title":"Flare rate thresholds for patient assessment of gout disease activity states","volume":"48","author":"Taylor","year":"2021","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2021.101716_bib40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s13075-020-02272-2","article-title":"Physical activity measured using wearable activity tracking devices associated with gout flares","volume":"22","author":"Elmagboul","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2021.101716_bib41","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13075-019-1944-5","article-title":"Comparison of an interactive voice response system and smartphone application in the identification of gout flares","volume":"21","author":"Elmagboul","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2021.101716_bib42","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/annrheumdis-2020-eular.3643","article-title":"Home-monitoring gout flares with a smartphone app \u2013 results of a feasibility study","volume":"79","author":"Pouls","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2021.101716_bib43","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s10067-015-3039-2","article-title":"\u201cYou want to get on with the rest of your life\u201d: a qualitative study of health-related quality of life in gout","volume":"35","author":"Chandratre","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2021.101716_bib44","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12905-015-0277-z","article-title":"\u201cWhy me? I don't fit the mould ... I am a freak of nature\u201d: a qualitative study of women's experience of gout","volume":"15","author":"Richardson","year":"2015","journal-title":"BMC Wom Health"},{"key":"10.1016\/j.berh.2021.101716_bib45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41927-019-0056-9","article-title":"Gout and sexual function: patient perspective of how gout affects personal relationships and intimacy","volume":"3","author":"Singh","year":"2019","journal-title":"BMC Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2021.101716_bib46","first-page":"214","article-title":"Maori experiences and perceptions of gout and its treatment: a kaupapa Maori qualitative study","volume":"5","author":"Te Karu","year":"2013","journal-title":"J\u00a0Prim Health Care"},{"issue":"4","key":"10.1016\/j.berh.2021.101716_bib47","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.semarthrit.2020.06.001","article-title":"The experience of a gout flare: a meta-synthesis of qualitative studies","volume":"50","author":"Stewart","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101716_bib48","article-title":"Gout flare severity from the patient perspective: a qualitative interview study","author":"Garcia-Guillen","year":"2020","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.berh.2021.101716_bib49","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/rheumatology\/keaa413","article-title":"Which factors predict discordance between a patient and physician on a gout flare?","volume":"60","author":"Jagpal","year":"2021","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.berh.2021.101716_bib50","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/ar4524","article-title":"Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study","volume":"16","author":"Singh","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2021.101716_bib51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13047-018-0313-y","article-title":"Experience of finding footwear and factors contributing to footwear choice in people with gout: a mixed methods study using a web-based survey","volume":"12","author":"Brenton-Rule","year":"2019","journal-title":"J\u00a0Foot Ankle Res"},{"issue":"1","key":"10.1016\/j.berh.2021.101716_bib52","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13075-017-1416-8","article-title":"Gout and comorbidity: a nominal group study of people with gout","volume":"19","author":"Singh","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.berh.2021.101716_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008323","article-title":"Mapping patients' experiences from initial symptoms to gout diagnosis: a qualitative exploration","volume":"5","author":"Liddle","year":"2015","journal-title":"BMJ Open"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694221000589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694221000589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:22:28Z","timestamp":1761499348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694221000589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1521694221000589"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2021.101716","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The challenge of gout flare measurement","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2021.101716","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101716"}}